Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

nt and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (vii) risks related to achieving positive clinical trial results; (viii) risks related to timely patient enrollment and retention in clinical trials; (ix) the results of the InterMune CAPACITY trials of pirfenidone differ in some respects from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone and there can be no assurance that the U.S. or European regulatory authorities will approve the use of pirfenidone for the treatment of IPF; (x) the results as reported by Shionogi concerning their Phase 3 trial may differ from those published or presented in a peer-reviewed forum; and (xi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.

Actimmune(R) is a registered trademark of InterMune, Inc. Pegasys(R) and Copegus(R) are registered trademarks of Roche.

                           Financial tables follow



                               InterMune, Inc.
         PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
             (unaudited, in thousands, except per share amounts)

                                Three Months Ended      Year Ended
                                      Dec 31              Dec 31
                                   2008      2007      2008      2007
    Revenue, net
      Actimmune                   $6,583    $8,809   $29,880   $53,420
      Collaboration revenue          818       81
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Today, Cryos International, the world’s largest ... U.S. facilities and inventory from New York City to ... Cryos’ relocation is a reflection of their increasing growth ... was completed during the first weekend of spring, March ... on April 6. The new facility in the Central ...
(Date:3/30/2015)... With recent advancements in residential solar ... major companies are getting into the Solar Energy wave. ... for renewable energy production, many homeowners are looking to ... is a new solar distribution company in California which ... qualifying homeowners to enjoy the benefits of solar energy ...
(Date:3/30/2015)... 2015  Heidrick & Struggles (Nasdaq: HSII ), the ... and culture shaping worldwide, today  announced that ... its global Healthcare and Life Sciences practice. As ... will lead a team of more than 80 partners, principals ... and Asia serving clients in the ...
(Date:3/30/2015)... US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ: ... University, on March 27 released pre-clinical data on experimental ... oral presentation by Professor Gil Mor MD ... Annual Scientific Meeting of the Society of Reproductive ... In both in vitro and in animal ...
Breaking Biology Technology:Cryos International Completes Groundbreaking Sperm Migration to Orlando, Florida 2Solara Power Announces Residential Solar Power with No Up-Front Fees 2Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4
... been banned by Allen Theaters of New Mexico. Revision Studios ... because it is too political. "Horror In The Wind" is ... orientation. , ... Alamogordo, NM (PRWEB) November 12, 2008 ...
... Mo., Nov. 11 An investor group in Trinity,Biotech ... and manufacturer of,diagnostic products whose shares are traded in ... initiated a campaign for,conversion of company ADRs to ordinary ... consider a change in the board., This campaign ...
... BMP,Sunstone Corporation (Nasdaq: BJGP ) ("BMP Sunstone" ... technical difficulties encountered on,today,s conference call, the company ... 2008. On this call, BMP Sunstone will give ... prevented the,Company from addressing all questions on today,s ...
Cached Biology Technology:Comedy 'Horror In The Wind' Banned In New Mexico 2Comedy 'Horror In The Wind' Banned In New Mexico 3BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call 2BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call 3
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... news clip that aired this week on Washington ... In a segment "The Next Great Thing", host ... new way to pay, and ,a really big breakthrough in ...
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/17/2015)... NEW YORK , March 17, 2015 /PRNewswire/ ... , the largest exhibition for service robots ever ... . RoboUniverse takes place on May 11-13, 2015 ... Sponsors and exhibitors for the event include: Acorn ... Motion Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... LANSING, Mich. Most organisms would die in the ... simple algae call it home, and their secrets to ... Garavito, Michigan State University professor of biochemistry and molecular ... how primitive red algae use horizontal gene transfer, in ...
... (Bronx, NY) Researchers at Albert Einstein College ... $12 million grant from the National Institutes of Health (NIH) ... in women. "As we move into the fourth decade ... impact on women, particularly in sub-Sahara Africa," said principal investigator ...
... the Wildlife Conservation Society Canada (WCS Canada) creates a ... in the Southern Canadian Rockies to the future impacts ... "safe passages and safe havens" were informed in ... westslope cutthroat trout, grizzly bears, wolverines, mountain goats and ...
Cached Biology News:Home toxic home 2Einstein receives $12 million grant to develop device for preventing HIV infection 2Einstein receives $12 million grant to develop device for preventing HIV infection 3'Climate-smart strategies' proposed for spectacular US-Canadian landscape 2